Matches in Wikidata for { <http://www.wikidata.org/entity/Q98216261> ?p ?o ?g. }
- Q98216261 description "article scientifique publié en 2020" @default.
- Q98216261 description "artículu científicu espublizáu n'agostu de 2020" @default.
- Q98216261 description "im August 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q98216261 description "scientific article published on 03 August 2020" @default.
- Q98216261 description "wetenschappelijk artikel" @default.
- Q98216261 description "наукова стаття, опублікована 3 серпня 2020" @default.
- Q98216261 name "Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study" @default.
- Q98216261 name "Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study" @default.
- Q98216261 type Item @default.
- Q98216261 label "Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study" @default.
- Q98216261 label "Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study" @default.
- Q98216261 prefLabel "Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study" @default.
- Q98216261 prefLabel "Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study" @default.
- Q98216261 P1433 Q98216261-6A2A16AD-A01C-4F65-AED6-7BFE5D207CBA @default.
- Q98216261 P1476 Q98216261-05E18D8D-62F8-4728-9EB8-824E3770E863 @default.
- Q98216261 P2093 Q98216261-1DD0CC89-831D-486B-B4C1-0AA92978923D @default.
- Q98216261 P2093 Q98216261-2CC76713-E753-4239-B9E9-E681A0BFEB5E @default.
- Q98216261 P2093 Q98216261-348A8BEF-EFAC-42C5-8A3B-19CF541A1A75 @default.
- Q98216261 P2093 Q98216261-34E0B34C-EC37-46F2-8AC0-F787C4A7A93C @default.
- Q98216261 P2093 Q98216261-6CDF28CB-AE66-494C-9ABC-0D752504A02D @default.
- Q98216261 P2093 Q98216261-7F5831DA-4D67-4CEC-9D9F-891C32EF7EB2 @default.
- Q98216261 P2093 Q98216261-85CB609D-68E7-40A9-AF8B-81E3AB565A4A @default.
- Q98216261 P2093 Q98216261-8FA5148E-76D9-4D69-B735-4FE427D19752 @default.
- Q98216261 P2093 Q98216261-935DDB77-B8B2-483E-8793-4B1BAACD8B70 @default.
- Q98216261 P2093 Q98216261-9C3F95CB-910E-4284-A255-EB176E683A09 @default.
- Q98216261 P2093 Q98216261-A1BDB086-9676-43CE-94A2-584150B4ABC1 @default.
- Q98216261 P2093 Q98216261-A8B50240-7857-4689-BD00-04605BACDC46 @default.
- Q98216261 P2093 Q98216261-C1DC930B-D173-46C2-ABE8-6EFEABBB2543 @default.
- Q98216261 P2093 Q98216261-C76813CC-4CD4-4D8F-9AA6-1A942E3F8636 @default.
- Q98216261 P2093 Q98216261-C7B2EAD4-4E8F-49C1-AEB4-EA6E9498F536 @default.
- Q98216261 P2093 Q98216261-DD784DD0-C9A0-465E-808D-F10480C19AC3 @default.
- Q98216261 P2093 Q98216261-E47AF3E2-FD02-478A-8F90-DA31DBD4E5E8 @default.
- Q98216261 P2093 Q98216261-F5ADC35E-4849-47F6-B4C3-A415167B2957 @default.
- Q98216261 P2093 Q98216261-F984B677-56EC-4883-880B-B7E0367B661A @default.
- Q98216261 P2093 Q98216261-FBBA00D2-258B-4E6E-A8BE-DC83D1D56F4A @default.
- Q98216261 P2860 Q98216261-092ED0D2-8D6C-43A7-9F1C-9068281A7111 @default.
- Q98216261 P2860 Q98216261-11882E88-DC09-4BAB-8E2D-6EF79545F0A0 @default.
- Q98216261 P2860 Q98216261-2E7B81E9-9ABF-4630-BFBD-8D51BB1116C9 @default.
- Q98216261 P2860 Q98216261-309D7C7E-3C54-4708-ABF2-CFA8C8585D80 @default.
- Q98216261 P2860 Q98216261-31B440A8-0E1B-4BDE-AA7B-34C29D7AD88D @default.
- Q98216261 P2860 Q98216261-33B83D61-D45C-4BA0-ABE5-F9E4B66AC853 @default.
- Q98216261 P2860 Q98216261-44E0FD2C-2F71-43FB-A381-527397C5442B @default.
- Q98216261 P2860 Q98216261-4D812835-5265-4443-9F10-7C0649B2F617 @default.
- Q98216261 P2860 Q98216261-52CEFBD3-EEE5-42B8-B7B4-ABE5712E861E @default.
- Q98216261 P2860 Q98216261-5B55BFAC-684A-4664-84C9-5CC4B8E886E9 @default.
- Q98216261 P2860 Q98216261-63854EDC-049C-414B-B951-F03F4E5A2D21 @default.
- Q98216261 P2860 Q98216261-7FFEC91D-FAA0-47AD-AB44-6585E6BAD764 @default.
- Q98216261 P2860 Q98216261-8302510B-F0AB-4532-BBB1-865F00D30DF1 @default.
- Q98216261 P2860 Q98216261-895C4198-B1FE-4787-8785-76B1DE18C244 @default.
- Q98216261 P2860 Q98216261-92491CB0-9892-43AF-B4EA-3DF1D4206CE7 @default.
- Q98216261 P2860 Q98216261-A1614327-11D1-4C99-9FB3-938F14D6D6B1 @default.
- Q98216261 P2860 Q98216261-A2A58807-EE6F-438E-A13A-698FF860ECAF @default.
- Q98216261 P2860 Q98216261-B5841E5F-7C36-4957-89B9-D8ED7264AC7E @default.
- Q98216261 P2860 Q98216261-B5F67F5F-000C-4EF9-9F3B-FA8F66DC5BE9 @default.
- Q98216261 P2860 Q98216261-B9BDBC9B-8F57-47ED-9CE5-F812508D2349 @default.
- Q98216261 P2860 Q98216261-BF3E94F8-F0BA-43B9-A7A7-E73D0EBD061D @default.
- Q98216261 P2860 Q98216261-C3231053-DF5F-4C36-A5D5-4903A6225BB0 @default.
- Q98216261 P2860 Q98216261-CC36EB29-05AE-47B9-8D17-B771126A9EE2 @default.
- Q98216261 P2860 Q98216261-D70056D0-3C35-44AC-BE81-6AE97FCB26AF @default.
- Q98216261 P2860 Q98216261-F23FD4EC-25A8-498D-AF9E-455A63BBCBC8 @default.
- Q98216261 P2860 Q98216261-FE9767AB-82EB-4F6A-B268-E7E5F81AA2C4 @default.
- Q98216261 P31 Q98216261-5983AC08-815A-4868-9B66-2629636113DC @default.
- Q98216261 P356 Q98216261-5F4A217D-4E7C-4F6B-986C-FFCFCC07E462 @default.
- Q98216261 P577 Q98216261-101FC1F1-6E25-4953-8785-B84C0CEEED6F @default.
- Q98216261 P698 Q98216261-E6A59F28-624C-4E52-A7DB-692ADE51E4BA @default.
- Q98216261 P921 Q98216261-9095B0E7-23BC-4E29-91F6-EB4E966868DD @default.
- Q98216261 P921 Q98216261-DC1ED4A8-F391-4255-8D86-82519E53D68C @default.
- Q98216261 P356 S2352-3026(20)30208-8 @default.
- Q98216261 P698 32758434 @default.
- Q98216261 P1433 Q26840042 @default.
- Q98216261 P1476 "Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study" @default.
- Q98216261 P2093 "Annalisa Chiappella" @default.
- Q98216261 P2093 "Christian Klein" @default.
- Q98216261 P2093 "Cristina Mendez" @default.
- Q98216261 P2093 "Fontanet Bijou" @default.
- Q98216261 P2093 "Gilles Salles" @default.
- Q98216261 P2093 "Jean-Marie Michot" @default.
- Q98216261 P2093 "Jeanette K Doorduijn" @default.
- Q98216261 P2093 "Kristen Hege" @default.
- Q98216261 P2093 "Marie José Kersten" @default.
- Q98216261 P2093 "Michael Pourdehnad" @default.
- Q98216261 P2093 "Patrick R Hagner" @default.
- Q98216261 P2093 "Pier Luigi Zinzani" @default.
- Q98216261 P2093 "Rafael Sarmiento" @default.
- Q98216261 P2093 "Reda Bouabdallah" @default.
- Q98216261 P2093 "Shailaja Uttamsingh" @default.
- Q98216261 P2093 "Silvia Mosulen" @default.
- Q98216261 P2093 "Tianlei Chen" @default.
- Q98216261 P2093 "Umberto Vitolo" @default.
- Q98216261 P2093 "Vincent Ribrag" @default.
- Q98216261 P2093 "Zariana Nikolova" @default.
- Q98216261 P2860 Q33433426 @default.
- Q98216261 P2860 Q34621900 @default.
- Q98216261 P2860 Q34663865 @default.
- Q98216261 P2860 Q35640007 @default.
- Q98216261 P2860 Q36934350 @default.
- Q98216261 P2860 Q37007346 @default.
- Q98216261 P2860 Q37178611 @default.
- Q98216261 P2860 Q37653274 @default.
- Q98216261 P2860 Q38286830 @default.